Quarterly review – changes in Prime Funds, our mutual fund recommendations

If you have noticed the portfolios of dynamic asset allocation funds with a fundamental-only driven model, you will see them sporting net equity holdings of under 40% now. In a market where over 40% of the stocks have a price earnings ratio of over 50 times or no PE at all (i.e., the company is loss-making), dynamic asset allocation funds can draw little comfort in holding higher allocation to equity. 

But what about equity funds that don’t have the luxury of moving away from equity even if valuations are discomforting? They either go with the market wave (read: momentum) or stick to what they know best – hold high quality stocks with sound metrics but less fancied in a bull market. The latter approach can result in paying a price – underperformance. 

Which one of these a fund opts for is based on the fund manager’s conviction (plus the kind of pressure he/she faces from the fund house to deliver!).

changes in Prime Funds

Bull market underperformance

When a bull market extends, defying fundamentals and driven largely by liquidity, portfolios that are designed strictly by fundamentals tend to underperform. If your otherwise sound mutual fund holdings have underperformed in recent quarters, this will likely be the primary reason. 

In this quarterly review, we could see both of the above play out. Funds that were severe underperformers turned the corner with jaw-dropping returns, either because their long-underperforming stocks suddenly started moving up or these funds joined the ‘momentum party’. A few others that were otherwise consistently in the top quartile, took sharp hits and trailed their index or peers by a significant margin in the past 1-2 quarters. 

These will be times for you to wait, not because it is a virtue but because it will likely keep you sane in this dizzying market. In line with the waiting game, we have little to no changes in our primary picks in Prime Funds. However, we have added some themes that might interest you. We have also called out funds where you would have seen pronounced underperformance, and let you know what to do.

About Prime Funds

If you are new to PrimeInvestor, this is what you need to know about Prime Funds: 

Prime Funds is our list of best mutual funds across equity, debt, and hybrid categories. We use Prime Ratings, our fund ratings, as a first filter and then use qualitative analysis to design our fund recommendations. Prime Funds is an enduring list of funds that you can use, and you will find a fund that meets any goal you’re looking to meet. 

Different categories: Prime Funds are separated into buckets, based on risk level in equity & hybrid funds, and timeframe in debt funds. Each of these draws from different SEBI-defined categories but we have classified them in a more user-friendly way than using the several dozens of SEBI categories. We do not go only by Prime Ratings but look at other factors as well to narrow the list and make the choices easy for you. 

Different styles: In Prime Funds, we’ve aimed at providing funds that follow different strategies for you to mix styles and diversify your portfolio with ease. The ‘Why this fund’ for each Prime Fund will brief its strategy, why we picked it, and how to use it in your portfolio.

Direct plans: We have specifically given the direct plans in Prime Funds. If you wish to know whether it is ok for you to use the regular plan, where we have a ‘buy,’ check our MF Review Tool (not our Ratings page). If the tool specifically calls out ‘buy through direct,’ it means that the expense ratio differential is high under the regular plan for that fund. You will be better off using the direct plan in such cases. You can also check the expense ratio differential using our new expense ratio tool.

Review: Our aim in reviewing the Prime Funds list every quarter is to ensure that we don’t miss any good opportunities that are coming up and we are not holding on to funds that are slipping. When we remove funds from the Prime Funds list, we tell you exactly what to do if you have invested in these funds. Funds we remove do not immediately call for a sell – it is just that they have slipped in performance marginally or there are better alternatives now. Unless our review tool says such funds are a ‘sell’, you can hold them (refer to our article on when to sell funds)

Using Prime Funds: You don’t need to hold every Prime Fund nor add any new fund we introduce to the list. Unless it fits your overall portfolio/strategy, or there is something lacking, there is little need for you to go on adding funds. Our idea of covering them in detail through some of our weekly calls is to let you know the strategy, style, and suitability in different portfolios. It is not a specific call to buy right away, unless we mention that it is a ‘tactical’ or ‘timing’ call.

We will now move to the changes we have done this quarter and what you should do about them.

Changes in equity funds

#1 Change in passive fund classification

Up until now, we listed passive funds under a distinct classification. This set of funds were a mix of large-cap, multi-cap and mid-cap indices, not to mention global indices or differentiated strategies. From now, we are removing this separate section and re-classifying these funds under the Equity – Moderate and Equity – Aggressive categories, based on the nature of the index. That is, the Equity – Moderate and Equity – Aggressive sections will each have two subsections – Active and Passive. 

The reason for this reclassification is that one, you know what risk to expect from each of the index funds. While this was already explained under the ‘Why this fund’ explanation we give, putting it under the relevant Moderate/ Aggressive buckets makes it much clearer for you. Two, it helps you compare and choose between an active fund and a passive fund in each of these risk buckets, and use the passive funds in the right way for your portfolio. Three, it helps clear up the confusion that many of you seem to have in treating index funds as a separate allocation in your portfolio instead of considering it as part of your moderate or high-risk allocations.

#2 Fund addition in Equity – moderate: Passive

The Nifty Low Volatility 30 is an index that is built by considering the stocks with the least volatility in the Nifty 100. We have had the ICICI Pru Nifty Low Vol 30 ETF for a long while now in our ETF recommendations. The AMC a few months ago introduced the fund option for this index, where it will invest in its ETF. 

This fund is the ICICI Pru Nifty Low Vol 30 ETF FoF. We have added this index fund to the Equity Moderate – Passive category. The index scores in keeping downsides contained, which helps in longer-term outperformance against the Nifty 100 index. We have covered the performance and suitability of the ICICI Pru Nifty Low Vol 30 in detail in earlier reports.

#3 Fund addition in Equity – Aggressive: Active

In this category, we added ICICI Pru India Opportunities fund, a thematic fund that seeks to generate returns by investing in opportunities that arise from special situations. By adding this fund, we strayed from our norm in two ways: one, we added a thematic fund in the Equity Aggressive category instead of the thematic bucket. Two, we added an active fund that did not cross our minimum track record cut-off. 

The reason for such a departure is as follows: First, despite being classified as thematic funds under SEBI’s rules, ICICI Pru India Opportunities fund’s portfolio is quite diversified, as the ‘special situations’ theme can be played across market cap segments and sectors. The definition of special situations is quite broad as well. Such situations could be in the form of regulatory or policy changes, corporate restructuring, company going through a rough patch due to challenges in the industry or internally and expected to come out of it. It can thus be a good multi-cap diversifier in a portfolio.

Second, at a time when the market is peppered with ‘special situations’ be it on the regulatory front, or individual companies facing challenges, we did not want to wait till the fund develops a ‘track record.’ Third, the fund has a value bias that comes from owning stocks that are facing challenges, which provides comfort on the valuation front. We also find this fund doing better than many other thematic funds with a similar strategy in its performance so far. 

The fund is a high-risk option, with the risks stemming from both its theme and the limited track record. The fund is suitable only for long-term portfolios of 7 years or above and should not form more than 5-10% of your portfolio. This cannot be a substitute for mid or small-cap funds in the Equity -aggressive category. We may also decide to take more active calls in the fund, when required. Investments can be in lumpsum or SIP with restricted exposure.

#4 Fund additions in Strategy/ thematic

We added two funds here. The first is DSP Healthcare. It is true that we missed the early rally in pharma when it began in end-2019 (we had not launched our research platform then). We never had the courage to pick the segment again given where valuations stood and the rally that took off. Now, with the sector cooling off a shade in the past 3-6 months, we see some opportunity to get in. 

DSP Healthcare is a sector fund that seeks to take exposure to both domestic and global healthcare (up to 25%) stocks. It is among the more diversified healthcare funds with an additional edge of exposure to US-based healthcare stocks. It focuses on medical device companies in the US as opportunities in this space are few in India. To give some background, the US Medical Equipment Index has a lower correlation to the Indian BSE Healthcare index. The fund itself is relatively new and does not have sufficient track record to assess performance, but currently competes well with similar top sector funds from Nippon India and Mirae Asset AMCs. The US diversification adds to the DSP fund’s uniqueness. 

As a sector fund, it needs a high risk appetite. Exposure should be curtailed to 5% of your portfolio. Consider averaging over a 6–12-month period at least as the relatively high valuations in this sector can cause a correction if liquidity dries up. Else, invest more on dips if you are an active observer of the markets. The fund needs a minimum time frame of 5-7 years. 

The second fund is Nippon India Consumption. The consumption theme is a relatively more secular one, and consumption appears to be reviving after the lockdown-hit slump. The relatively more ‘defensive’ nature of the core consumer stocks, such as FMCG, also lend some heft to the theme. 

Outside of FMCG, though, consumption extends to several sectors. Media, entertainment, financial services, recreation, home improvement, automobiles, retail, and much more all fall under the consumption theme.

Nippon India Consumption is among the older funds in the consumer theme. It compares well with other consumption funds across metrics. The fund’s portfolio is an eclectic mix of stocks across consumption pockets. While its top holdings are more concentrated, especially towards FMCG stocks, the fund is still well-diversified. 

Our other recommendation in this theme is BNP Paribas India Consumption. The Nippon fund is less reliant on financial exposure than the BNP fund and sports somewhat more direct consumer plays. You can invest in either of the funds, and the theme can be held for the longer term as well.

#5 Fund removal in Strategy/ thematic

We have removed UTI MNC from our theme bucket in this review. The MNC theme is among the poor performing themes in this bull rally and it didn’t help that some of the FMCG, IT MNCs in UTI MNC’s basket delivered tame returns. We had introduced this fund in this category anticipating a market correction as MNC funds hold up well in such market phases. However, this scenario did not play out. We think you will be better off taking fresh exposure to other diversified strategies than miss the rally, while it lasts. 

Stop SIPs, if any in the fund but continue to hold investments made so far as this can still help contain downsides in the event of a correction. Fresh lumpsum investments can be avoided as well.

#6 Taking note of underperformance

As we explained at the outset of this report, several funds that were otherwise consistently at the top have slid lower as previous underperformers served up stellar returns.

One of these is Kotak Flexicap which has lingered below the Nifty 500 TRI since about August last year. The reasons remain that top picks have not been the outperformers in this rally. These stocks are otherwise sound and do fit the fund’s ‘value’ bias, such as Larsen & Toubro or Bharat Electronics. Others, such as Hindustan Unilever are more defensive bets that can help should markets take a breather. The fund has got several calls right, such as picking up Infosys and ICICI Bank, or cement stocks or steel plays.

Given the nature of the market rally and the uncertain position it is in now, against the fund’s strategy and portfolio, we’re still inclined to wait it out with this fund. The underperformance has not worsened, suggesting that there is an attempt to turn performance around. Shorter-term returns over periods such as 1 month and 3 months show that the fund is trying to improve, with some periods of outperformance over the index; this is yet to firmly sustain. That said, performance may yet take time to fully move back above the index unless the market scenario changes very quickly. 

The other is DSP Midcap, which has an even starker 1-year underperformance over its benchmark and peers. What we said in the beginning of this report applies well to this fund. DSP Midcap missed the bull rally by staying away from stocks that shot up – and a good number with inferior financial metrics or business fundamentals. If you ran a screener on this fund’s portfolio, you would find that the fund has not compromised on quality or growth metrics.

The rally over the past year was driven by commodities, value stocks some power ad capital good stocks and select cyclical stocks. DSP Midcap did not own these meaningfully and had marginally underweight exposure to financials (which it has mostly bridged now). And those it owned, be it Federal Bank or City Union Bank did not perform. What seems right about its portfolio is that it holds stocks with sound balance sheet and a healthy earnings growth – although they simply refuse to gain from the current liquidity-driven bull rally. 

While the fund still manages to keep itself above its benchmark on a rolling-3-year return basis, its 1-year performance may leave you worried. We observe from rolling 1-month returns that the margin of underperformance over the index is reducing in recent times. While we are confident that a correcting market will quickly bring this fund back in form, we may otherwise have to watch for a few more quarters to see if the fund is able to course correct.  You can continue staying invested in the fund until we have any update.

The summary of the funds added and removed is below.

Changes in debt funds

We have made no changes in debt funds for the following reasons. 

First,  at this time, the direction the debt market will take is uncertain. The tug-of-war between inflation, interest rates markets expect, and the RBI’s efforts to prevent rates from rising too much and hurt growth persists. 

Second, the funds we recommend across time-frames are among the best in their categories. We find few options outside these that are consistent enough in terms of strategy or portfolio to merit an inclusion, especially given the uncertainty over where and how much rates can move. 

Third, the narrowing spreads between top-rated debt and government debt also don’t offer much in terms of new fund opportunities. To ensure you get decent returns in these uncertain times, we have cautiously added a credit risk fund as part of our debt longer-term recommendations. In shorter-term recommendations, we have included funds that take marginal, controlled risks to offer better returns.

Fourth, with the increase in the bank deposit insurance and the sweeping changes in the way the deposit insurance works, high-returning deposits of the smaller and/or riskier banks become attractive propositions. In the shorter-term timeframes, these deposits become especially competitive compared to debt funds.

In the debt space, therefore, note the following points:

  • Where there are specific pockets of opportunities, we will issue calls on these. Our recent highlighting of the opportunity in SDLs and ways to play them are an example. We will continue to look for such higher yields that you can lock into, especially if rates turn lower making specific target-maturity funds/ETFs attractive.
  • You can include short-maturity funds (3 months to 1.5 years and 1.5-3 years buckets in Prime Funds) in your portfolio, even if you have a long-term horizon. These funds are the best-suited at times when rates are uncertain as they will reflect any change quickly.
  • Do not exit your longer-term debt funds. They are not wrong funds to hold, provided you have the right timeframe for it. These funds will simply take longer to reflect any rise in interest rates. They will be low-returning in the short term. You need to hold through this period. If you have additional surplus to invest, you can choose to add short-maturity funds if you’re concerned over the current low yields.
  • In the above context, we’d like to make note of SBI Magnum Constant Maturity, part of our 5+ year Prime Funds bucket. This fund’s double-digit returns have dwindled down to less than 5% for the past year. This is not a worrying trend, and comes as the duration rally peters out. As the likelihood of further rate cuts fade – the 10-year Government bond yields have moved to 6.3%-levels this year from the sub-6% levels they were earlier. High returns from these funds is not the norm. Constant maturity funds will go through phases of underperformance as the rate cycle transitions out of a downward phase. The reason for including constant maturity funds in long-term portfolios is simply to cushion equity risks, avoid risks of a fund taking wrong duration or credit calls, and offer a fuss-free, semi-passive, long-term debt component.
  • You can add on fixed deposits that offer higher rates to supplement your fixed income allocation. We have updated Prime Deposits to include such options, so do refer for recommendations. If you already are interested in any bank’s deposit programme, run a check on its financial health using our Bank FD tool before zeroing in.

Finally, a short note on our Prime ETFs, our ETF recommendations. We have made no significant changes in ETFs. We have removed one ETF only – ICICI Pru S&P BSE 500 ETF. The ETF had poor trading volumes, though it still kept tracking error controlled. Volumes were improving, until the trend took a turn over the past few months. The 3-month average traded value was just about Rs 13 lakh a day. This makes it hard to deploy investments, and therefore we have pulled it out of the recommended list until we see a steady improvement in volumes. If you already hold the ETF, continuing holding as tracking error is low. If you still wish to make additional investments in the ETF, spread it out over several days and invest small amounts only each time.

The Prime Funds list can be accessed here.

The Prime ETFs list can be accessed here.

More like this

31 thoughts on “Quarterly review – changes in Prime Funds, our mutual fund recommendations”

  1. Mohanasundaram R

    Dear Ms. Bhavana\Vidya,

    On index-based ETF, could you please publish an article on how equal weight strategy such as “DSP Nifty 50 Equal Weight ETF” compares to a regular one with some back-tracking analysis.

    Thanks,
    Mohan

    1. Sure, we’ll look at equal-weight indices. They are outperforming at present, but their prospects depend on the nature of the market cycle. No promises on when, though 🙂 – thanks, Bhavana

  2. Hello!
    Thanks for excellent quarterly review of funds,as usual.
    Just one query about your Sell call on all F T Funds due to uncertainty of AMC’s business continuation plans–
    1) In my view,this aspect needs revisiting due to resolution of various issues.
    2) Whether respective Fund’s performance was also considered in making a Sell call.
    Thanks

    1. hello Sir:
      1. YEs, we have stated that we will keep an open mind. Let all the money be repaid first.
      2. No, only partly, we have stated where performance was an issue. Overall – it was a judgement call on the way the fund house botched up events and handled investors and the lack of confidence it will suffer from. Like many other prolongd underperformers, Franklin funds too bounced back in this market when we wrote about it. But we have seen many such bounces and then slippages. Consistency was always poor. So, yes we continue to track them and will see what changes. We are closed to anything.
      thanks, Vidya

  3. Karthikeyan Alagappa Rajendran

    Hello Team,

    In today’s ET Wealth cover story by your team about selling the laggards, I find HDFC midcap opportunities was mentioned as laggard to be sold. However in my MF review tool review, this fund is being shown as a ‘Hold”. Which advice is final and current?

    Thanks

    1. There is no correct one. ET study was about identifying large AUM players that are also underperformers. Our regular review toolt akes the entire universe…please stick with our call but please check them quarterly as the hold call is just about there with index and can fall in future even with marginal underperformance. thanks, Vidya

Comments are closed.

Hold On

You are being redirected to another page,
it may take a few seconds.
Login to your account
OR

Become a PrimeInvestor!

Get stock & mutual fund recommendations

Start registration

Start registration

OR
user icon
user icon
user icon

Terms & Conditions

A copy of the T&C has been sent to your email.

Last modified on February 18, 2025

This website www.primeinvestor.in (“Website”) is owned and operated by PrimeInvestor Financial Research Pvt. Ltd. (“RA”), a SEBI-registered Research Analyst with Registration No. INH200008653.

Through the Website, the RA allows clients to access research recommendations, research reports, and model portfolios, along with tools, personal finance products, and articles, on the payment of a subscription fee (“Research Services”). The terms ‘RA’ or ‘us’ or ‘we’ refer to PrimeInvestor Financial Research Pvt Ltd (SEBI RA Registration No INH200008653) who are the owners of this Website and offering the Research Services. The term ‘you’ and ‘client’ refers to the subscriber of the Services on the Website. The RA provides the Research Services subject to the notices, terms, and conditions set forth in these Terms. By accepting these Terms when you subscribe to the Research Services, you provide your consent to abide by these Terms.

Most Important Terms and Conditions (MITC)

[Forming part of the Terms and Conditions for providing research services]

  1. These terms and conditions, and consent thereon are for the research services provided by the Research Analyst (RA) and RA cannot execute/carry out any trade (purchase/sell transaction) on behalf of the client. Thus, the clients are advised not to permit RA to execute any trade on their behalf.
  2. The fee charged by RA to the client will be subject to the maximum amount prescribed by SEBI/ Research Analyst Administration and Supervisory Body (RAASB) from time to time (applicable only for Individual and HUF Clients).
    Note:
    • SEBI's current cap on fee is Rs 1,51,000/- per annum per family of client for all research services of the RA.
    • The fee limit does not include statutory charges.
    • The fee limits do not apply to a non-individual client / accredited investor.
  3. RA may charge fees in advance if agreed by the client. Such advance shall not exceed the period stipulated by SEBI; presently it is one quarter. In case of pre-mature termination of the RA services by either the client or the RA, the client shall be entitled to seek refund of proportionate fees only for the unexpired period.
  4. Fees to RA may be paid by the client through any of the specified modes like cheque, online bank transfer, UPI, etc. Cash payment is not allowed. Optionally the client can make payments through Centralized Fee Collection Mechanism (CeFCoM) managed by BSE Limited (i.e. currently recognized RAASB).
  5. The RA is required to abide by the applicable regulations/ circulars/ directions specified by SEBI and RAASB from time to time in relation to disclosure and mitigation of any actual or potential conflict of interest. The RA will endeavor to promptly inform the client of any conflict of interest that may affect the services being rendered to the client.
  6. Any assured/guaranteed/fixed returns schemes or any other schemes of similar nature are prohibited by law. No scheme of this nature shall be offered to the client by the RA.
  7. The RA cannot guarantee returns, profits, accuracy, or risk-free investments from the use of the RA's research services. All opinions, projections, estimates of the RA are based on the analysis of available data under certain assumptions as of the date of preparation/publication of research report.
  8. Any investment made based on recommendations in research reports are subject to market risks, and recommendations do not provide any assurance of returns. There is no recourse to claim any losses incurred on the investments made based on the recommendations in the research report. Any reliance placed on the research report provided by the RA shall be as per the client's own judgement and assessment of the conclusions contained in the research report.
  9. The SEBI registration, Enlistment with RAASB, and NISM certification do not guarantee the performance of the RA or assure any returns to the client.
  10. For any grievances,
    • Step 1: the client should first contact the RA using the details on its website or following contact details:
      Customer care: [email protected]
      Grievance officer: [email protected], ATTN: Srikanth Meenakshi
      Compliance officer: [email protected], ATTN.: Bhavana Acharya
      Principal officer: [email protected], ATTN.: Vidya Bala
    • Step 2: If the resolution is unsatisfactory, the client can also lodge grievances through SEBI's SCORES platform at www.scores.sebi.gov.in
    • Step 3: The client may also consider the Online Dispute Resolution (ODR) through the Smart ODR portal at https://smartodr.in
  11. Clients are required to keep contact details, including email id and mobile number/s updated with the RA at all times.
  12. The RA shall never ask for the client’s login credentials and OTPs for the client’s Trading Account, Demat Account, and Bank Account. Never share such information with anyone including RA.

By browsing, viewing, using the Website and subscribing to the Research Services provided therein you consent to and agree to comply with these Terms and Conditions of subscription (“Terms”).

The RA reserves the right to change or modify the Website, the contents thereof and these Terms at any time. All modifications to these Terms & Conditions will be posted on the Website and will become effective immediately upon such posting. Changes once made will be communicated to the client. Continued use of the Website shall be construed as acceptance of the revisions to the Terms by conduct.

The following terms and conditions include but are not limited to minimum mandatory terms and conditions to clients as stipulated by SEBI.

1. Availing the research services

By accepting delivery of the research service, the client confirms that he/she has elected to subscribe to the research service of the RA at his/her sole discretion. The RA confirms that Research Services shall be rendered in accordance with the applicable provisions of the SEBI RA Regulations.

2. Obligations on RA

The RA shall be bound by the SEBI Act and all the applicable rules and regulations of SEBI, including the RA Regulations and relevant notifications of Government, as may be in force, from time to time.

3. Client Information and KYC

The client shall furnish all such details in full as may be required by the RA in its standard form with supporting details, if required, as may be made mandatory by Research Analyst Administration and Supervisory Body(RAASB)/SEBI from time to time. RA shall collect, store, upload and check KYC records of the clients with KYC Registration Agency (KRA) as specified by SEBI from time to time.

4. Standard Terms of Service

The consent of client shall be taken on the following understanding:

“I / We have read and understood the terms and conditions applicable to a research analyst as defined under regulation 2(1)(u) of the SEBI (Research Analyst) Regulations, 2014, including the fee structure.

I/We are subscribing to the research services for our own benefits and consumption, and any reliance placed on the research report provided by research analyst shall be as per our own judgement and assessment of the conclusions contained in the research report.

I/We understand that –

  1. Any investment made based on the recommendations in the research report are subject to market risk.
  2. Recommendations in the research report do not provide any assurance of returns.
  3. There is no recourse to claim any losses incurred on the investments made based on the recommendations in the research report.”

The declaration of the RA is as follows:

  1. We are duly registered with SEBI as an RA pursuant to the SEBI (Research Analysts) Regulations, 2014 and our registration details are: registration no SEBI INH200008653, with registration date 19th August, 2021
  2. We have the registration and qualifications required to render the services contemplated under the RA Regulations, and the same are valid and subsisting;
  3. Research analyst services provided by us do not conflict with or violate any provision of law, rule or regulation, contract, or other instrument to which it is a party or to which any of its property is or may be subject;
  4. The maximum fee that may be charged by the RA is ₹1.51 lakhs per annum per family of client. Our current fee structure, the term and duration of our subscription for our Research Services, can be viewed on our website here: https://primeinvestor.in/prime-pricing
  5. The recommendations provided by us as part of the Research Services do not provide any assurance of returns.

5. Consideration and mode of payment

The client shall duly pay to the RA the agreed fees for the services that RA renders to the client and statutory charges, as applicable. Such fees and statutory charges shall be payable through the specified manner and mode(s)/ mechanism(s).

The payment of fees shall be through a mode that shows traceability of funds. Such modes include but are not limited to credit cards/debit cards/ UPI/ net banking or any other mode specified by SEBI from time to time. However, the fees shall not be in cash.

6. Risk factors

  1. Investments are subject to market risk. Investing or trading in financial products involves risk. Past performance of the recommendation is not an indication of future returns. Past performance of the RA is not an indicator of future performance. Past performance of the security is not an indication of future returns.
  2. There are no assurances or guarantees that the objectives of any investment in financial products will be achieved.
  3. The names of financial products mentioned herein do not in any manner indicate their prospects or returns. The performance in the equity may be adversely affected by the performance of individual companies, changes in the market place and industry specific and macro-economic factors.
  4. The performance of the investments/ products recommended by the RA are subject to a wide range of risks, including but not limited to: performance of the respective companies, changes in equity and debt market conditions, micro and macro factors and forces affecting equity and debt markets, general levels of interest rates and interest rate risk, credit risk, liquidity risk, reinvestment risk, economic slowdown, volatility & illiquidity of the stocks, risks associated with trading volumes, liquidity and settlement systems in equity and debt markets and/or such other circumstance beyond the control of the RA or any of its Associates.
  5. Other risk factors include that may affect the performance of the investments/ products recommended by the RA include but are not limited to economic policies, changes of Government and its policies, acts of God, acts of war, civil disturbance, sovereign action and /or such other acts/ circumstance beyond the control of the RA or any of its Associates.
  6. The recommendations provided by the RA as part of its Research Services may not be suitable to all categories of investors.
  7. The client should read all scheme and security related documents carefully before investing.
  8. Returns and performance figures mentioned in the research report represent past performance and should not be constituted to be future returns or guaranteed returns.

7. Conflict of interest

The RA shall adhere to the applicable regulations/ circulars/directions specified by SEBI from time to time in relation to disclosure and mitigation of any actual or potential conflict of interest. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

General disclosures: PrimeInvestor Financial Research Pvt Ltd (with brand name PrimeInvestor) is an independent research entity offering research services on personal finance products to customers. We are a SEBI registered Research Analyst (Registration: INH200008653). PrimeInvestor Financial Research Pvt. Ltd., its employees, directors or agents, do not have any material adverse disciplinary history as on the date of publication of this report.

Restrictions on trading: To ensure no conflict of interest, the RA declares as follows:

  1. Personal trading activities of the individuals employed as research analysts shall be monitored, recorded and subject to a formal approval by the directors or compliance officer of PrimeInvestor Financial Research Private Limited.
  2. Research analysts employed by PrimeInvestor Financial Research Private Limited or their associates or relatives shall not:
    • Deal/ trade in stocks recommended/ tracked by the research analyst within 30 days before and five days after the publication of a research report;
    • Deal/ trade in securities that the research analyst reviews in a manner contrary to the given recommendation;
    • Purchase or receive securities of the issuer before the issuer's initial public offering, if the issuer is principally engaged in the same types of business as companies that the research analyst follows or recommends.

Disclosures with respect to Research and Recommendations Services:

  1. The RA or its directors or any of its officer/employee does not trade in securities which are subject matter of recommendation.
  2. The RA, or any of its officers, directors, employees, or subsidiaries have not received any compensation/ benefits whether monetary or in kind, from the AMC, company, government, bank or any other product manufacturer or third party, whose products are the subject of its Research Services or investment information.
  3. The Research Analysts who have prepared the research reports that form part of the Research Services (“Research Analyst”) certify that all of the views expressed in the research report accurately reflect their views about the subject company or subject security.
  4. The RA or directors or employees or Research Analyst certify that no part of their compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.
  5. The Research Analyst has not served as director, officer or employee in the subject company, AMC or insurance company of the mutual fund or insurance policy that is the subject of this report, or company whose bonds, NCDs, fixed deposits or other savings products that is the subject of this report.
  6. The Research Analyst or their relatives do not have any known direct or indirect material conflict of interest including long/short positions in the subject company.
  7. The Research Analyst may hold investments in the stocks, mutual fund schemes, bonds, fixed deposits, insurance policies, or other products that are the subject of the recommendations provided as part of the Research Services. The Research Analyst certifies that they will not act in a manner contrary to their views on these securities except in the event of significant news or event or change in personal financial circumstances and without formal approval from the directors of PrimeInvestor Financial Research Pvt. Ltd. or the compliance officer.
  8. There are no actual or potential conflicts of interest arising from any connection to or association with any issuer of products/ securities, including any material information or facts that might compromise its objectivity or independence in the carrying on of the Research Services. Such conflict of interest shall be disclosed to the client as and when they arise.
  9. The RA or its directors or its employee or its associates have not managed or co-managed the public offering of any company. The RA or its directors or its employee or its associates have not received any compensation for investment banking or merchant banking of brokerage services from the subject company. The RA or its directors or its employee or its associates have not received any compensation for products or services other than above from the subject company. The RA or its directors or its employee or its associates have not received any compensation or other benefits from the Subject Company or 3rd party in connection with the research report/ recommendation.
  10. The subject company of its research recommendations was not a client of the RA or its directors or its employee or its associates during twelve months preceding the date of recommendation services provided.
  11. The RA or its directors or its employee or its associates has not served as an officer, director or employee of the subject company. Research Analysts has not been engaged in market making activity of the subject company.

PrimeInvestor Financial Research Pvt. Ltd., its Associates, the Research Analysts or their relatives holds ownership of 1% or more, in respect of the said issuer company(ies)? – NO

8. Termination of service and refund of fees:

The RA may terminate or suspend rendering of Research Services to the client in the following circumstances:

  1. On account of suspension/cancellation of registration of RA by SEBI. In case of suspension of certificate of registration of the RA for more than 60 (sixty) days or cancellation of the RA registration, RA shall refund the fees, on a pro rata basis for the period from the effective date of cancellation/ suspension to end of the client’s subscription period.
  2. The RA voluntarily chooses to terminate its Research Service. In the event of such termination of the Research Service, the RA shall refund the fees, on a pro rata basis for the period from the date of such termination of research service to end of the client’s subscription period.

9. Grievance redressal and dispute resolution:

Any grievance related to:

  1. nonreceipt of research report, or
  2. missing pages or inability to download the entire report, or
  3. any other deficiency in the research services provided by RA

shall be escalated promptly by the client to the person/employee designated by RA, in this behalf as under:

Name: Bhavana Acharya
Designation: Director & Compliance Officer, PrimeInvestor Financial Research Pvt Ltd
Email: [email protected]

The RA shall be responsible to resolve grievances within 7 (seven) business working days or such timelines as may be specified by SEBI under the RA Regulations.

RA shall redress grievances of the client in a timely and transparent manner. Any dispute between the RA and his client may be resolved through arbitration or through any other modes or mechanism as specified by SEBI from time to time.

If the client is not satisfied with the response of the RA, he/she can lodge his/her grievances with SEBI at scores.sebi.gov.in. Alternatively, the client may also write to any of the offices of SEBI. For any queries, feedback or assistance, please contact SEBI Office on Toll Free Helpline at 1800 22 7575 / 1800 266 7575

Details on grievances are available on the Website as follows: https://primeinvestor.in/ra-grievance/

10. Additional clauses:

Scope of the Research Service: The Research Services will be limited to providing independent research recommendation and shall not be involved in any advisory or portfolio allocation services. The Research Services are not meant to be tailor-made or customized solutions that specifically apply to each client based on his/her risk profile.

The RA never guarantees the returns on the recommendation provided. Investor shall take note that investment/trading in stocks/Index or other securities is always subject to market risk. Past performance is never a guarantee of same future results. The RA shall not be responsible for any loss to the Investors.

This service is not directed for access or use by anyone in a country, especially the USA, Canada or the European Union countries, where such use or access is unlawful or which may subject PrimeInvestor Financial Research Pvt Ltd or its affiliates to any registration or licensing requirement.

The Research Service, including recommendations, research reports, updates, and other information will be accessible through the RA’s website https://primeinvestor.in only. Such recommendations and updates will not be provided over phone calls.

Fees: Our current fee structure, the term and duration of our subscription for our Research Service, can be viewed on our website: https://primeinvestor.in/prime-pricing. Eligibility for any discounts is ascertained at the time the client subscribes. Any such discount and its tenure shall be at the discretion of the RA.

Subscription and access to content services fall under the purview of Goods and Services Tax (GST) as per the current indirect taxation policy, Government of India. Unless otherwise indicated, prices stated on our website are exclusive of applicable GST, any applicable value added tax (VAT) or other sales taxes. We are a business-to-consumer (B2C) service provider and we do not commit to provide any input tax credit on GST charged on subscription to our Research Service.

We may change the Subscription Fees and charges then in effect, or add new fees or charges which will take effect at the end of the client’s subscription period, by giving notice in advance and an opportunity to cancel renewal of the subscription.

Subscription Access & Renewal: Subscription to the Website commences immediately on the realisation of payment of the Subscription Fees. Subscriptions are set to be renewed automatically at the end of the subscription period.

Unless the client notifies us before the end of his/her subscription period, or the client cancels the auto-renewal mandate within the period specified by law, that the client does not wish to renew his/her subscription, the client’s subscription will renew for the period defined by the client’s subscription plan. We will charge the subscription using the same payment method that you previously used.

Although the client may notify to us his/her intention to his/her subscription, such notice will only take effect at the end of his/her then current subscription period, and he/she will not receive a refund other than as set out under Clause 8 in these Terms.

The client may notify us of his/her wish to cancel his/her subscription by sending an email to [email protected]. The client must provide at least 5 business days advance notice for this to be implemented.

Refunds: There can be no cancellation and refund of subscription fee paid once the subscription is active, other than as stated in Clause 8 of these Terms. If the client is entitled to a refund as specified under Clause 8 of these Terms, the RA will credit that refund to the card or other payment method used by the client to submit payment, unless it has expired - in which case the RA will contact the client to proceed with the refund. If we do issue a refund or credit due to circumstances outside the obligations specified under Clause 8, we are under no obligation to issue the same or a similar refund in the future.

General disclaimers: The recommendations made herein in the Research Services are expression of views and/or opinions and should not be deemed or construed to be advice for the purpose of purchase or sale of any security, nor a solicitation or offering on any investment/ trading opportunity on behalf of the company, AMC, insurance company, or issuer of security referred to herein.

The content and research reports generated by the RA does not constitute or is not intended to constitute an offer to buy or sell, or a solicitation to an offer to buy or sell financial products, units or securities.

The information/ opinion/ views mentioned in research reports or by the RA are not meant to serve as a professional guide to the client or recipients of this Report. The research report, recommendation, or any other content published by the RA do not assure or guarantee any minimum or fixed returns to the client or recipients of the reports/ recommendations/ content.

Use of this information is at the client’s own risk. The client must make his/ her own investment decisions based on his/her specific investment objective and financial position and using such independent advisors as he/she believes necessary. The services rendered by the RA are on a best-effort basis. All information in the content or research report of the RA is provided on an as is basis. Information is believed to be reliable but the RA does not warrant its completeness or accuracy and expressly disclaim all warranties and conditions of any kind, whether express or implied.

While due care has been taken to ensure that the disclosures, information, and opinions given are fair and reasonable, PrimeInvestor Financial Research Pvt Ltd and/or none of its officers, directors, partners, employees, agents, subsidiaries, affiliates or business associates shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way whatsoever from the information/ opinions/ views contained in the research report and recommendations that form part of the Research Service, and/or mails, social media or notifications issued by PrimeInvestor Financial Research Pvt Ltd or any other agency appointed/authorised by PrimeInvestor Financial Research Pvt Ltd. Returns and performance figures mentioned in the research report represent past performance and should not be constituted to be future returns or guaranteed returns.

Any agreements, transactions or other arrangements made between the client and any third party named on (or linked to from) the Website are at your own responsibility and entered into at your own risk. Any information that you receive via the Website, whether or not it is classified as “real time”, may have stopped being current by the time it reaches you. Market price information may be rounded up/down and therefore may not be entirely accurate.

The purpose of these disclosures is to provide essential information about the Research Services in a manner to assist and enable the prospective client/client in making an informed decision for engaging in Research Services before onboarding.

History, present business and background: PrimeInvestor Financial Research Private Limited is registered with SEBI as Research Analyst with registration no. INH200008653. The Research Analyst got its registration on August 19, 2021 and is engaged in offering research and recommendation services.

Disciplinary history: There are no pending material litigations or legal proceedings against the Research Analyst. As on date, no penalties / directions have been issued by SEBI under the SEBI Act or Regulations made thereunder against the Research Analyst relating to Research Analyst services.

Details of the RA's associates: No associates.

Usage of Website Content: This Website is controlled and operated by the RA. All material, including research reports, recommendations, portfolios, ratings, lists of financial products, illustrations, statements, opinions, views, photographs, products, images, artwork, designs, text, graphics, logos, button icons, images, audio and video clips and software (collectively, “Content”) are protected by copyrights, trademarks and other intellectual property rights that are owned and controlled by the RA or by other parties that have licensed their material to us.

Except where otherwise agreed in writing with the RA, material on the Website is solely for the client’s personal, non-commercial use. Except as provided below, the client must not copy, reproduce, republish, upload, post, transmit or distribute such material in any way, including by e-mail or other electronic means and whether directly or indirectly and the client must not assist any other person to do so.

Without the prior written consent of the RA, modification of the materials, use of the materials on any other web site or networked computer environment or use of the materials for any purpose other than personal, non-commercial use is a violation of the copyrights, trademarks and other proprietary rights, and is prohibited. Any use for which the client receives any remuneration, whether in money or otherwise, is a commercial use for the purposes of these Terms.

The client may occasionally distribute a copy of a research report, or a portion of the same, from the Website in non-electronic form to a few individuals without charge, provided the client includes all copyright and other proprietary rights notices in the same form in which the notices appear, original source attribution, and the phrase “Used with permission from PrimeInvestor Financial Research Pvt. Ltd.”

While the client may occasionally download and store research reports or information from the Website for his/her personal use, he/she may not otherwise provide others with access to the same. The foregoing does not apply to any sharing functionality we provide through the Website that expressly allows the client to share Content or links to Content with others. In addition, the client may not use Content he/she has downloaded for personal use to develop or operate an automated trading system or for data or text mining.

The client agrees not to rearrange or modify the Content available through the Website. The client agrees not to display, post, frame, or scrape the Content for use on another website, app, blog, product or service, except as otherwise expressly permitted by these Terms. You agree not to create any derivative work based on or containing the research products and Content. The framing or scraping of or in-line linking to the Services or any Content contained thereon and/or the use of webcrawler, spidering or other automated means to access, copy, index, process and/or store any Content made available on or through the Services other than as expressly authorized by us is prohibited.

The client further agrees to abide by exclusionary protocols (e.g., Robots.txt, Automated Content Access Protocol (ACAP), etc.) that may be used in connection with the Research Services. The client may not access parts of the Research Services to which he/she is not authorized, or attempt to circumvent any restrictions imposed on your use or access of the Services.

As a general rule, the client may not use the Content, including without limitation, any Content made available through one of our RSS Feeds, in any commercial product or service, without our express written consent.

The client may not create apps, extensions, or other products and services that use our Content without our permission. The client may not aggregate or otherwise use our Content in a manner that could reasonably serve as a substitute for a subscription to the Website.

The client may not access or view the Services with the use of any scripts, extensions, or programs that alter the way the Services are displayed, rendered, or transmitted to you without our written consent.

The client agrees not to use the Services for any unlawful purpose. We reserve the right to terminate or restrict the client's access to the Website if, in our opinion, the client's use of the Services may violate any laws, regulations or rulings, infringe upon another person's rights or violate these Terms.

Prohibited content: The Website includes comments sections, blogs and other interactive features that allow interaction among clients and between clients and the RA. We call the information posted by or contributed by users “Contributed Content.” In the course of availing of the Research Services or uploading any post or comment on the Website, the client shall not post any Contributed Content that (i) contains nude, semi-nude, sexually suggestive photos, (ii) tends or is likely to abuse, harass, threaten, impersonate or intimidate other users of the Website and/or Research Services, (iii) is lascivious or appeals to the prurient interest or if its effect is such as to tend to deprave and corrupt persons who are likely to use or have access to the Website and/or Services, or (iv) otherwise violates, is prohibited or restricted by applicable law, rule or regulation, is offensive or illegal or violates the rights of, harms or threatens the safety of other users of the Website and/or Services (collectively “Prohibited Content”).

We reserve the right to cease to provide the client with the Research Services or access to the Website, or terminate your subscription, with immediate effect and without notice and liability, for violating these Terms, applicable law, rules or regulations and reserves the right to remove Prohibited Content which is in violation of these Terms, or is otherwise abusive, illegal or disruptive. The determination of whether any content constitutes Prohibited Content, violates these Terms, or is otherwise abusive illegal or disruptive, is subject to the sole determination of the Firm.

Changes to Research Services: We are constantly endeavouring to improve the quality of Research Services provided to our clients. Due to this, the form and nature of the Research Services provided may change from time to time without any prior notice to the client. We reserve the right to introduce and initiate new features, functionalities, components to the Website and/or Research Services and/or change, alter, modify, or discontinue existing ones without any prior notice to the client.

Warranty and liability disclaimer: The Website, Research Services, and all the materials and services, included on or otherwise made available to the client through this Website is provided by the RA on an “as is” and “as available” basis without any representation or warranties, express or implied except otherwise specified in writing. Without prejudice to the foregoing paragraph, the RA does not warrant that:

  • This Website and/or Research Services will be constantly available, or available at all;
  • The information on this Website or provided through the Research Services is complete, true, accurate or not misleading; or
  • The quality of any products, services, information, or other material that you obtain through the Website or Services will meet your expectations.

The RA, to the fullest extent permitted by law, disclaims all warranties, whether express or implied, including the warranty of merchantability, fitness for particular purpose and non-infringement. The RA makes no warranties about the accuracy, reliability, completeness, or timeliness of the Website, Research Services, Content, Contributed Content, Services, software, text, graphics and links.

The RA does not warrant that this Website, Research Services, information, content, materials, or any other material included on or otherwise made available to you through this Website, their servers, or electronic communication sent by the RA are free of viruses or other harmful components.

Nothing on this Website constitutes, or is meant to constitute, advice of any kind.

Indemnification: The client:

  1. Represents, warrants and covenants that no materials of any kind provided by him/her will:
    1. Violate, plagiarise, or infringe upon the rights of any third party, including copyright, trademark, privacy or other personal or proprietary rights; or
    2. Contain libellous, Prohibited Content or other unlawful material;
  2. Hereby agree to indemnify, defend and hold harmless the RA and all of the RA’s officers, directors, owners, agents, customers/clients, information providers, affiliates, licensors and licensees (collectively, the “Indemnified Parties”) from and against any and all liability and costs, including, without limitation, reasonable advocate’s fees, incurred by the Indemnified Parties in connection with any claim arising out of any breach by the client of these Terms or the foregoing representations, warranties and covenants. The client shall cooperate as fully as reasonably required in the defence of any such claim. The RA reserves the right, at its own expense, to assume the exclusive defence and control of any matter subject to indemnification by the client.

Applicable law: This Website, including the Content and Contributed Content and information contained herein, and the provision of Research Services shall be governed by the Securities and Exchange Board of India, laws of the Republic of India and the courts of Chennai, India which shall retain exclusive jurisdiction to entertain any proceedings in relation to any disputes arising out of the same. As such, the laws of India shall govern any transaction completed using this Website.

Information gathered and tracked: Information submitted or collected on the Website or pursuant to the use of the Services is stored in a database. Specifically, we store the username, name, e-mail address, contact number, as submitted or collected on our Website or through the provision of the Research Services. We may use such information to send out occasional promotional materials, including alerts on new Services available, or other promotional and marketing material relating to our clients and customers.

In accordance with the Information Technology Act 2000, the name and the details of the Grievance Officer at PrimeInvestor is provided below:

Mr. Srikanth Meenakshi
PrimeInvestor Financial Research Pvt. Ltd., Registered office: 659, 4th Avenue, D-Sector, Anna Nagar Western Extension, Chennai 600 101.
Email: [email protected]

11. Mandatory notice:

Clients shall be requested to go through Do’s and Don’ts while dealing with RA as specified in SEBI master circular no. SEBI/HO/MIRSD-POD-1/P/CIR/2024/49 dated May 21, 2024 or as may be specified by SEBI from time to time.

12. Optional Centralised Fee Collection Mechanism:

SEBI has operationalized a centralized fee collection mechanism for IA and RA. Under this mechanism, clients shall pay fees to IAs/RAs through a designated platform/portal administered by a recognized Administration and Supervision body. This is an optional mechanism for the registered entities. At this time, PrimeInvestor has opted out of this fee collection mechanism. Therefore, all subscription payments for the Research Services will be through the modes as specified in Clause 5 of these Terms.

Enter the OTP sent to (Edit)
By doing this you agree to our terms & conditions
Didn't receive OTP? Resend

Have an account?
Login To Your Account
OR
Don’t have an account ? Register for free